Current status of CAD

The global prevalence of coronary heart disease will increase from 186 million in 2017 to 208 million in 2021, with a CAGR of 2.8%. Preliminary statistics show that the global prevalence of coronary heart disease will be around 213 million in 2022.


Fast report

Reduce learning time
for young physician

Q:What lesions can μFR® be used to evaluate?

A:Stable angina/unstable angina, preoperative evaluation of noncriminal lesions in patients with infarction; evaluation of postoperative outcome of treatment; evaluation of microvascular lesions; evaluation of lesions in combination with diabetes mellitus, hypertension, aortic stenosis, and other diseases.

Q:Is the μFR safe?

A:The μFR® test does not require additional materials and does not come into direct contact with the human body, posing no additional risks or side effects. The examination process itself does not create any risks. It is characterized by safety and economy.

Q:What benefits can μFR screening provide?

A: Reduces the risk of adverse cardiovascular events in patients by 34% over 2 years, improves patients' quality of life, and reduces the likelihood of reoperation or infarction, and thus rehospitalization. ② Has health economics value, overall reduction in total patient healthcare expenditure. ③ Makes interventional procedures more precise, determining whether they need to be done, how to do them, and predicting what the results will be when they are done. ④ Easier assessment of invisible microvascular status, allowing for more "subtle" treatment.